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Despite almost 2500 clinical trials involving stem cells, there is not
a single clinical problem that is routinely treated with stem cell
therapy because it is better than the standard of care. For all the
progress we have made in the fast moving ﬁeld of regenerative
medicine, the capacity to routinely restore functional tissue
following traumatic injury or degenerative disease is still beyond
reach.
Have the technologies that we now have at hand, such as 3-D
printing, deep genomic sequencing and manipulation, or directed
stem cell differentiation in the dish, outpaced our understanding
of the signals that orchestrate natural development? Should we
attempt to restore the epimorphic regeneration potential of
humans, releasing the newt within us? Is it even possible to
restore a non-blastemal regeneration response in organs like the
human brain? It is tempting to extrapolate from the remarkable
regenerative capacity of the mammalian neonate and envision the
engineering of a similar response in the adult. Or perhaps we
should be satisﬁed with moving the needle from the default
inﬂammation/scar tissue formation response toward a more
constructive and functional response, and leave true regeneration
to “more primitive” species such as the newt until we understand
the upstream signals that regulate these processes.
To advance the pace of progress, scientists are now adopting
multidisciplinary strategies, combining evolutionarily conserved
principles of developmental biology, immunology, stem cell
biology, tissue engineering, biomechanics, and medicine in
ex vivo and in vivo approaches. Recreating the supportive micro-
environment of a regenerating zebraﬁsh heart in a patient will
require a more profound understanding of the 30% differences in
protein coding genes between ﬁsh and man, and dynamic cellular
processes that rapidly modulate immune response to bypass the
physical blockade of infarct scar, promote revascularization to
prevent more cell death, and provide the necessary extracellular
milieu for restoration of functional cardiac contractile tissue. We’re
not there yet, but there’s promising light on the horizon.
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